Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines
János Szebeni, Gert Storm, Julia Y. Ljubimova, Mariana Castells, Elizabeth J. Phillips, Keren Turjeman, Yechezkel Barenholz, Daan J.A. Crommelin, Marina A. Dobrovolskaia
Topics & Concepts
NanomedicineAnaphylaxisVaccinationMedicineImmunizationMessenger RNACoronavirus disease 2019 (COVID-19)Adverse effectImmunologyIntensive care medicineVirologyAllergyImmune systemNanotechnologyPharmacologyBiologyDiseaseNanoparticleInternal medicineInfectious disease (medical specialty)GeneMaterials scienceBiochemistrySARS-CoV-2 and COVID-19 ResearchDrug-Induced Adverse ReactionsHeparin-Induced Thrombocytopenia and Thrombosis